(182 days)
Not Found
No
The description focuses on mechanical oscillation and operator-controlled frequency, with no mention of AI or ML terms or functionalities.
Yes.
The device is intended to provide airway clearance therapy to improve mobilization of bronchial secretions, which directly addresses a health condition.
No
The device is used for airway clearance therapy to mobilize bronchial secretions by applying high-frequency chest wall oscillations. It treats a condition rather than diagnosing it.
No
The device description clearly states the primary components are an air oscillator and an inflatable vest, which are hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The description clearly states that the ThAIRapy® Vest is a high-frequency chest wall oscillator that applies external pressure to the chest to mobilize bronchial secretions. It is a physical therapy device, not a diagnostic test performed on a biological sample.
- Intended Use: The intended use is for airway clearance therapy, a treatment method, not for diagnosing a condition.
The device description and intended use clearly place this device in the category of a therapeutic device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The intended use of the ThAIRapy® System is to promote airway clearance or improve bronchial drainage by enhancing mobilization of bronchial secretions where external manipulation of the thorax is the physician's choice of treatment. The indications typically follow the Clinical Practice Guideline published by the American Association for Respiratory Care (AARC) 1991.
The intended use of the modified ThAIRapy® Vest is the same as the predicate device, which is to provide airway clearance therapy when external manipulation of thorax is the physician's choice of treatment. Indications for this form of therapy are described by the American Association for Respiratory Care (AARC) in the Clinical Practice Guidelines for Postural Drainage Therapy. According to AARC guidelines, the goals of airway clearance therapy are to improve mobilization of bronchial secretions, match ventilation and perfusion, and normalize functional residual capacity. Specific indications for external manipulation of the thorax include evidence or a suggestion of retained secretions, evidence that the patient is having difficulty with secretion clearance, or presence of atelectasis caused by mucus plugging.
Product codes (comma separated list FDA assigned to the subject device)
73 BYI
Device Description
The ThAIRapy® System is a high-frequency chest wall oscillator designed be used in a wide variety of settings for enhancing the mobilization of bronchial secretions. The primary components of the ThAIRapy® System include an air oscillator and an inflatable vest. Oscillating positive pressure air pulses are applied to the vest by the air oscillator. The resulting pressure pulses cause the vest to inflate and deflate against the chest of the patient creating high-frequency chest wall oscillation and mobilization of bronchial secretions. Frequency of the pulse air is operator controlled and adjustable from 5 to 25 Hz.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
chest
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Pressures obtained in the inflatable vests for the ThAIRapy® System were recorded and compared with pressures for the predicate. Results depict pressures that are consistent with the predicate.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 868.5665 Powered percussor.
(a)
Identification. A powered percussor is a device that is intended to transmit vibration through a patient's chest wall to aid in freeing mucus deposits in the lung in order to improve bronchial drainage and that may be powered by electricity or compressed gas.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows a stylized symbol that resembles a combination of the letter 'A' and a musical note. The symbol is drawn with thick, black lines, giving it a bold and graphic appearance. The overall design is abstract and could be interpreted in various ways, depending on the viewer's perspective.
ericanBiosystems
JUN 2 4 1997 01 Dec. 96
SUMMARY OF SAFETY AND EFFECTIVENESS
This summary of safety and effectiveness is being submitted in accordance with the requirements of SMDA 1990.
Submitter: American Biosystems, Inc., 1375 Wolters Blvd., Suite 116, St. Paul MN 55110 (612)490-1468 Contact: Phillip R. Rose, Quality Assurance and Regulatory Affairs
Name of Device: ThAIRapy® System Classification: Powered Percussor, Class II
Predicate Device: ThAIRapy® System, K884098
Description of Device:
The ThAIRapy® System is a high-frequency chest wall oscillator designed be used in a wide variety of settings for enhancing the mobilization of bronchial secretions. The primary components of the ThAIRapy® System include an air oscillator and an inflatable vest. Oscillating positive pressure air pulses are applied to the vest by the air oscillator. The resulting pressure pulses cause the vest to inflate and deflate against the chest of the patient creating high-frequency chest wall oscillation and mobilization of bronchial secretions. Frequency of the pulse air is operator controlled and adjustable from 5 to 25 Hz.
Intended Use:
The intended use of the ThAIRapy® System is to promote airway clearance or improve bronchial drainage by enhancing mobilization of bronchial secretions where external manipulation of the thorax is the physician's choice of treatment. The indications typically follow the Clinical Practice Guideline published by the American Association for Respiratory Care (AARC) 1991.
Comparison of Technological Characteristics:
The modified ThAIRapy® System has been thoroughly tested to determine the impact of the changes on safety and effectiveness. All modifications have been evaluated according to categories of Electrical, Chemical, Output, Operation, and Infection Control. In all categories, the modified device remained substantially equivalent to the predicate ThAIRapy® System. The major difference to the original predicate ThAIRapy® System is the change of the air blower component to a blower from another supplier and changing generation of the air pulse oscillations from a rotary valve to utilization of reciprocating bellows. Usage of an inflatable vest with two connecting hoses continues as the same method as the original predicate for providing the external manipulation of the thorax.
Performance Testing:
Pressures obtained in the inflatable vests for the ThAIRapy® System were recorded and compared with pressures for the predicate. Results depict pressures that are consistent with the predicate.
Local 612 490 1468 American Biosystems, Inc Toll Free 800 426 4224 1375 Wolters Boulevard, Suite 116 Fax 612 490 1484 St.Paul, MN 55110
1
DEPARTMENT OF HEALTH & HUMAN SERVICES
.. . ...
Image /page/1/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three stylized human profiles facing to the right.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
11 13, 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Mr. Phillip R. Rose American Biosystems, Inc. 1375 Wolters Boulevard, Suite 116 St. Paul, Minnesota 55110
Re: K965192 ThAIRapy® System Regulatory Class: II (two) Product Code: 73 BYI Dated: April 4, 1997 Received: April 7, 1997
Dear Mr. Rose:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labelinq, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2 - Mr. Phillip R. Rose
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Thomas J. Callehan
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(K) Number (if known),
ThAIRapy® Vest System_ Device Name___________________________________________________________________________________________________________________________________________________________________
Indications for use:
The intended use of the modified ThAIRapy® Vest is the same as the predicate device, which is to provide airway clearance therapy when external manipulation of thorax is the physician's choice of treatment. Indications for this form of therapy are described by the American Association for Respiratory Care (AARC) in the Clinical Practice Guidelines for Postural Drainage Therapy.1 According to AARC guidelines, the goals of airway clearance therapy are to improve mobilization of bronchial secretions, match ventilation and perfusion, and normalize functional residual capacity. Specific indications for external manipulation of the thorax include evidence or a suggestion of retained secretions, evidence that the patient is having difficulty with secretion clearance, or presence of atelectasis caused by mucus plugging.
965 92
1 Bronchial Hygiene Guidelines Committee, American Association for Respiratory Care. A ARC clinical practice guideline: postural drainage therapy. Respiratory Care 1991; 36: 1418 - 1426.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Richard N. Phillips
(Division Sign-Off Dunsion of Cardiovasca and Neurological Devic 510(k) Number
Prescription Use
(Per 21 CFR 801.109)
✓
: OR
Over The Counter Use